EVO
Eaton Vance Ohio Municipal Income Trust

98
Mkt Cap
$1.27B
Volume
29,821.00
52W High
$5.64
52W Low
$2.84
PE Ratio
-8.50
EVO Fundamentals
Price
$4.06
Prev Close
$4.15
Open
$4.11
50D MA
$3.73
Beta
1.06
Avg. Volume
46,400.71
EPS (Annual)
-$0.5981
P/B
1.45
Rev/Employee
$178,593.71
Loading...
Loading...
News
all
press releases
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
Zacks·13d ago
News Placeholder
More News
News Placeholder
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in...
PR Newswire·11mo ago
News Placeholder
Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction
Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction Halozyme Confirms Proposal to Combine with Evotec for 11.00 Per Share in an All-Cash Transaction PR...
PR Newswire·1y ago
News Placeholder
Evotec and X-Chem Collaborate to Accelerate Early-Stage Drug Discovery
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) and X-Chem, leader in DNA-encoded library (DEL) technology, today announced a collaboration agreement focused...
Business Wire·1y ago
News Placeholder
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS
EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS EVOTEC AND VARIANT BIO ENTER STRATEGIC PARTNERSHIP TO DISCOVER AND DEVELOP FIBROSIS TREATMENTS PR...
PR Newswire·2y ago
News Placeholder
Evotec And Claris Ventures Streamline Access to Accelerate Programmes from Claris's Portfolio Companies into The Clinic
CLARIS'S PORTFOLIO COMPANIES RECEIVE EASY ACCESS TO EVOTEC'S FULL RANGE OF PRE-CLINICAL AND CLINICAL DEVELOPMENT AND MANUFACTURING CAPABILITIESAGREEMENT BUILDS ON SUCCESSFUL COLLABORATION BETWEEN...
Accesswire·2y ago
News Placeholder
Evotec SE (EVO, $7.83) Moving Average Convergence Divergence (MACD) Histogram turned positive on February 7, 2024
This is a Bullish indicator signaling EVO's price could rise from here. Traders may explore going long the stock or buying call options...
Tickeron - Technical Analysis·2y ago
News Placeholder
Just - Evotec Biologics Expands Development and Manufacturing Agreement with ABL for Broadly Neutralising Antibodies Against HIV
JUST - EVOTEC BIOLOGICS TO PROVIDE DEVELOPMENT AND PHASE I CLINICAL MANUFACTURING OF BROADLY NEUTRALISING ANTIBODY AGAINST HIVAGREEMENT BUILDS ON PREVIOUS NIAID-FUNDED COLLABORATION TO DEVELOP A...
Accesswire·2y ago
News Placeholder
Evotec SE (EVO, $7.65) RSI Indicator left the oversold zone on February 06, 2024
This is a signal that EVO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Stocks·2y ago
News Placeholder
Evotec SE (EVO, $8.19) RSI Indicator left the oversold zone on January 24, 2024
This is a signal that EVO's price could be shifting from a downtrend to an uptrend. Traders may consider buying the stock or exploring call options...
Tickeron - Technical Analysis·2y ago

Latest EVO News

View

Advertisement|Remove ads.

Advertisement|Remove ads.